Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21747409 | 0.96 | CES2 (0.34) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL28524702 | 0.94 | CES2 (0.38) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL21747400 | 0.94 | LMNA (0.33) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL7714802 | 0.75 | CES2 (0.43) | LMNAUSP2SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL8171802 | 0.75 | PKM (0.47) | LMNAPOLBHPGDTP53KMT2A | |
| SCHEMBL12723334 | 0.74 | ALDH1A1 (0.42) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL248930 | 0.72 | ALDH1A1 (0.39) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL3715609 | 0.72 | TSHR (0.33) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL5916915 | 0.72 | HPGD (0.33) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL21747296 | 0.72 | HPGD (0.39) | LMNAPOLBUSP2SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11970495-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2024-04-30 | — | — | US | disclosed |
| US-11945817-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2024-04-02 | — | — | US | disclosed |
| US-20230257379-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230242527-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2023-08-03 | — | — | US | disclosed |
| US-11655249-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2023-05-23 | — | — | US | disclosed |
| US-20210253570-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2021-08-19 | — | — | US | disclosed |
| CN-113004271-A | Indolizine derivative and application thereof in medicine | 杭州安道药业有限公司 | 2021-06-22 | — | — | CN | disclosed |
| US-11021478-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2021-06-01 | — | — | US | disclosed |
| CN-108484598-B | Indolizine derivative and application thereof in medicine | 杭州安道药业有限公司 | 2021-03-02 | — | — | CN | disclosed |
| US-20200165242-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257379-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | LMNA 2594/4885POLB 4303/4885USP2 4524/4885 |
| US-11021478-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | LMNA 2594/4885POLB 4303/4885USP2 4524/4885 |
| US-11970495-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | LMNA 2594/4885POLB 4303/4885USP2 4524/4885 |
| US-20230242527-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | LMNA 2594/4885POLB 4303/4885USP2 4524/4885 |
| US-11945817-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | LMNA 2594/4885POLB 4303/4885USP2 4524/4885 |
| US-20210253570-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | LMNA 2594/4885POLB 4303/4885USP2 4524/4885 |
| US-11655249-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | LMNA 2594/4885POLB 4303/4885USP2 4524/4885 |
| US-20200165242-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | LMNA 2594/4885POLB 4303/4885USP2 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.